论文部分内容阅读
目的:探讨SALL4/BMI-1基因在多发性骨髓瘤患者中基因表达及其临床意义。方法:应用实时荧光定量PCR技术,对54例多发性骨髓瘤,6例巨球蛋白血症进行SALL4/BMI-1基因的定量检测,并选择10例健康志愿者作为对照组。结果:SALL4/BMI-1基因在健康对照骨髓中不表达,在巨球蛋白患者中低表达,而骨髓瘤患者明显增高有显著差异性(P<0.05)。在骨髓瘤各亚型中,轻链型表达明显高于其他亚型(P<0.05),而且SALL4/BMI-1基因的表达与骨髓瘤的分呈正相关(P<0.05)。BMI-1与SALL4的表达规律一致,两者表达水平有显著相关性(P<0.01)。结论:SALL4/BMI-1基因在骨髓瘤患者高表达,而且与骨髓瘤的临床分期和轻链型有密切关系,可能作为临床判断预后和检测微小残留的一个指标。
Objective: To investigate the gene expression of SALL4 / BMI-1 in patients with multiple myeloma and its clinical significance. Methods: Quantitative detection of SALL4 / BMI-1 gene was performed in 54 cases of multiple myeloma and 6 cases of macroglobulinemia by real-time fluorescence quantitative PCR. Ten healthy volunteers were selected as control group. Results: The SALL4 / BMI-1 gene was not expressed in the bone marrow of healthy controls and was low in macroglobulin patients, but significantly higher in patients with myeloma (P <0.05). The expression of SALL4 / BMI-1 gene in myeloma subtypes was significantly higher than that in other subtypes (P <0.05), and the expression of SALL4 / BMI-1 gene was positively correlated with myeloma (P <0.05). The expressions of BMI-1 and SALL4 were consistent, and the expression levels of BMI-1 and SALL4 were significantly correlated (P <0.01). CONCLUSIONS: SALL4 / BMI-1 gene is highly expressed in myeloma patients and closely related to the clinical stage and light chain of myeloma. It may serve as an index for clinical judgment of prognosis and detection of minimal residual disease.